Head-to-head · free
Kyntra Bio, Inc. vs 908 Devices Inc.
KYNB vs MASS — return on capital, cash generation, margins and balance sheet side by side.
KYNB
3 / 7
measures where KYNB leads
MASS
4 / 7
measures where MASS leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | KYNB · FY2025 | MASS · FY2025 |
|---|---|---|
| Revenue | $6.4M | $56.2M |
| Net income | $183.5M | $19.5M |
| Revenue growth (yearly, multi-year) | -59.3% | 7.4% |
| Free cash flow | (4.8M) | (24.6M) |
| Free cash flow margin | -74.7% | -43.9% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | — | 15.1% |
| Gross margin | 91.4% | 50.6% |
| Operating margin | -704.1% | -45.7% |
| Net debt / EBITDA | 1.06x | — |
Figures are as reported by each company; latest fiscal year shown.
Where Kyntra Bio, Inc.'s cash went (FY2025)
- Capital spending
- $38000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where 908 Devices Inc.'s cash went (FY2025)
- Capital spending
- $955000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free